There are currently 2700 clinical trials in Boston, Massachusetts looking for participants to engage in research studies. Trials are conducted at various facilities, including Massachusetts General Hospital, Dana Farber Cancer Institute, Brigham and Women's Hospital and Beth Israel Deaconess Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Delta GREENS Food is Medicine Intervention
NCT06358859
Recruiting
Though the Mississippi Delta has a rich agricultural history and some of the nation's most fertile soil, residents have experienced the legacy of slavery and economic exploitation through food insecurity and poverty for generations. This project focuses on Bolivar, Washington, and Sunflower, contiguous counties in the Delta that are designated as health disparity populations. Over 65% of the 100,000 residents are Black/African American and \~30% live at or below the poverty level. Obesity rates... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
05/20/2025
Locations: Tufts University, Boston, Massachusetts
Conditions: Cardiometabolic Risk Factors, Diabetes, High Blood Pressure, Obesity, Nutrition Security
Register for Updates
A Novel Digital Application (SHIFT) to Improve Outcomes for Hematopoietic Stem Cell Transplant Survivors
NCT06541002
Recruiting
This research study is evaluating the efficacy of a novel self-administered digital application for improving sexual health outcomes, quality of life, and psychological distress in hematopoietic stem cell transplant survivors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2025
Locations: Massachusetts General Hospital (MGH), Boston, Massachusetts
Conditions: Sexual Dysfunction, Stem Cell Transplant Complications, Bone Marrow Transplant Complications
Register for Updates
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
NCT06577987
Recruiting
This is a first-in-human, multicenter, open-label, phase 1 study to evaluate safety, tolerability, and efficacy of CID-078, a Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
05/20/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Refractory Solid Tumor, Cancer, Lung Cancer, Triple Negative Breast Cancer, Breast Neoplasms, Neuroendocrine Tumors, Neuroendocrine Carcinoma, RB1 Gene Mutation
Register for Updates
Multi-Component Breath Alcohol Intervention Phase 3
NCT06994962
Recruiting
This is the third stage of a three-stage, NIH-funded study to develop and test a multi-modal intervention concerning blood/breath alcohol concentration for young adults who drink heavily. The multimodal intervention will be made up of brief telehealth counseling and psychoeducation and use of three existing mobile technologies. The brief counseling/psychoeducation and mobile technologies provide personalized feedback regarding blood or breath alcohol content. The long-term goal of use of these m... Read More
Gender:
ALL
Ages:
Between 18 years and 25 years
Trial Updated:
05/20/2025
Locations: Northeastern University, Boston, Massachusetts
Conditions: Alcohol Use, Alcohol Drinking, Drinking Behavior
Register for Updates
A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.
NCT03219450
Recruiting
This research study is studying a novel type of CLL vaccine as a possible treatment for chronic lymphocytic leukemia (CLL) The names of the study interventions involved in this study are: * Personalized NeoAntigen Vaccine * Poly-ICLC * Cyclophosphamide * Pembrolizumab
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Lymphocytic Leukemia
Register for Updates
Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial
NCT03706833
Recruiting
To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System in patients with degenerative mitral regurgitation (DMR) who have been determined to be at prohibitive risk for mitral valve surgery by the Heart Team, and in patients with functional mitral regurgitation (FMR) on guideline directed medical therapy (GDMT)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts +2 locations
Conditions: Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
Register for Updates
Resilience and Equity in Aging, Cancer, and Health (REACH)
NCT04674267
Recruiting
The purpose of this multi-phase research study is to understand how consultation of cancer care with a geriatrician can best improve outcomes for older adults with gastrointestinal malignancies.
Gender:
ALL
Ages:
70 years and above
Trial Updated:
05/19/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Gastric Cancer, Colon Cancer, Esophageal Cancer, Rectal Cancer, Pancreatic Cancer, Gastrointestinal Cancer
Register for Updates
TriPRIL CAR T Cells in Multiple Myeloma
NCT05020444
Recruiting
This research study involves the study of TriPRIL CAR T Cells for treating people with relapsed or refractory multiple myeloma and to understand the side effects when treated with TriPRIL CAR T Cells. This research study involves the study drugs:. * TriPRIL CAR T Cells * Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Multiple Myeloma, Multiple Myeloma in Relapse, Refractory Multiple Myeloma
Register for Updates
CARv3-TEAM-E T Cells in Glioblastoma
NCT05660369
Recruiting
The goal of this research study is to determine the best dose of CARv3-TEAM-E T Cells for treating participants with glioblastoma. The name of the treatment intervention used in this research study is: -CARv3-TEAM-E T Cells (or Autologous T lymphocytes).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Glioblastoma, Malignant Glioma, Recurrent Glioblastoma, Recurrent Glioma
Register for Updates
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer
NCT05680922
Recruiting
This is a phase 1, first-in-human, open-label, multicenter, dose escalation and expansion study of DLL3-targeted chimeric antigen receptor T-cells in subjects with extensive stage small cell lung cancer or large cell neuroendocrine lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Small Cell Lung Cancer Extensive Stage, Large Cell Neuroendocrine Carcinoma of the Lung
Register for Updates
Cardiac RADIoablation Versus Repeat Catheter Ablation: a Pivotal Randomized Clinical Trial Evaluating Safety and Efficacy for Patients With High-risk Refractory Ventricular Tachycardia (RADIATE-VT)
NCT05765175
Recruiting
RADIATE-VT is a pivotal, multicenter, randomized trial comparing safety and efficacy between cardiac radioablation (CRA) using the Varian CRA System and repeat catheter ablation (CA), for patients with high-risk refractory ventricular tachycardia (VT) who have experienced VT recurrence after CA and are candidates for additional CA.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/19/2025
Locations: Brigham & Women's Hospital, Boston, Massachusetts
Conditions: Tachycardia, Ventricular
Register for Updates
A Study of Opportunistic Salpingectomy to Prevent Ovarian Cancer
NCT06312124
Recruiting
The purpose of this study is to find out how many participants are interested in a surgical preventive procedure after watching an educational video. Before and after watching the video, participants will complete questionnaires in the clinic.
Gender:
FEMALE
Ages:
45 years and above
Trial Updated:
05/19/2025
Locations: Dana Farber Cancer Institute (Data Collection Only), Boston, Massachusetts
Conditions: Surgery
Register for Updates